Cited by

• TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.

  Gatt ME, Takada K, Mani M, Lerner M, Pick M, Hideshima T, Carrasco DE, Protopopov A, Ivanova E, Sangfelt O, Grandér D, Barlogie B, Shaughnessy JD Jr, Anderson KC, Carrasco DR. Gatt ME, et al. Br J Haematol. 2013 Jul;162(2):210-20. doi: 10.1111/bjh.12365. Epub 2013 May 7. Br J Haematol. 2013. PMID: 23647456 Free PMC article.
• A peptide nucleic acid _targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatment.

  Alagpulinsa DA, Yaccoby S, Ayyadevara S, Shmookler Reis RJ. Alagpulinsa DA, et al. Cancer Biol Ther. 2015;16(6):976-86. doi: 10.1080/15384047.2015.1040951. Epub 2015 May 21. Cancer Biol Ther. 2015. PMID: 25996477 Free PMC article.
• Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

  Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Morton LM, et al. Blood. 2006 Jan 1;107(1):265-76. doi: 10.1182/blood-2005-06-2508. Epub 2005 Sep 8. Blood. 2006. PMID: 16150940 Free PMC article.
• Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.

  Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y, Cattoretti G, Ye BH. Ding BB, et al. Blood. 2008 Feb 1;111(3):1515-23. doi: 10.1182/blood-2007-04-087734. Epub 2007 Oct 19. Blood. 2008. PMID: 17951530 Free PMC article.
• The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.

  Sprynski AC, Hose D, Caillot L, Réme T, Shaughnessy JD Jr, Barlogie B, Seckinger A, Moreaux J, Hundemer M, Jourdan M, Meissner T, Jauch A, Mahtouk K, Kassambara A, Bertsch U, Rossi JF, Goldschmidt H, Klein B. Sprynski AC, et al. Blood. 2009 May 7;113(19):4614-26. doi: 10.1182/blood-2008-07-170464. Epub 2009 Feb 18. Blood. 2009. PMID: 19228610 Free PMC article.